Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Saul

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Angiology|August 1, 1997
Postoperative mitral valve abscess. A case reportS Pamidi, P J Leo, B Saul, et al.
Gynecologic Oncology|February 1, 1987
A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinomaJ J Kavanagh, P B Saul, J T Wharton, et al.
Laryngo- Rhino- Otologie|December 4, 2013
[Radiological findings of the nasal septum in CT scan in patients with deviated noses]B Saul, G Rettinger, M Scheithauer, et al.
Gynecologic Oncology|January 1, 1986
A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancerJ J Kavanagh, D M Gershenson, P B Saul, et al.
Annals of the New York Academy of Sciences|September 15, 1994
The inhibitory glycine receptor. A candidate protein of signal transduction in neuroendocrine tissueC M Becker, C Kling, C Mülhardt, et al.
Gynecologic Oncology|May 1, 1986
A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancerJ J Kavanagh, L J Copeland, D M Gershenson, et al.
Cancer Treatment Reports|November 1, 1985
Continuous-infusion vindesine in refractory carcinoma of the cervix: a phase II trialJ J Kavanagh, P B Saul, D M Gershenson, et al.
FEBS Letters|August 15, 1994
Point mutation of glycine receptor alpha 1 subunit in the spasmodic mouse affects agonist responsesB Saul, V Schmieden, C Kling, et al.
Cancer Treatment Reports|January 1, 1985
Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trialJ J Kavanagh, P B Saul, L J Copeland, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 27, 1999
Novel GLRA1 missense mutation (P250T) in dominant hyperekplexia defines an intracellular determinant of glycine receptor channel gatingB Saul, T Kuner, D Sobetzko, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Angiology|August 1, 1997
Postoperative mitral valve abscess. A case reportS Pamidi, P J Leo, B Saul, et al.
Gynecologic Oncology|February 1, 1987
A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinomaJ J Kavanagh, P B Saul, J T Wharton, et al.
Laryngo- Rhino- Otologie|December 4, 2013
[Radiological findings of the nasal septum in CT scan in patients with deviated noses]B Saul, G Rettinger, M Scheithauer, et al.
Gynecologic Oncology|January 1, 1986
A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancerJ J Kavanagh, D M Gershenson, P B Saul, et al.
Annals of the New York Academy of Sciences|September 15, 1994
The inhibitory glycine receptor. A candidate protein of signal transduction in neuroendocrine tissueC M Becker, C Kling, C Mülhardt, et al.
Gynecologic Oncology|May 1, 1986
A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancerJ J Kavanagh, L J Copeland, D M Gershenson, et al.
Cancer Treatment Reports|November 1, 1985
Continuous-infusion vindesine in refractory carcinoma of the cervix: a phase II trialJ J Kavanagh, P B Saul, D M Gershenson, et al.
FEBS Letters|August 15, 1994
Point mutation of glycine receptor alpha 1 subunit in the spasmodic mouse affects agonist responsesB Saul, V Schmieden, C Kling, et al.
Cancer Treatment Reports|January 1, 1985
Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trialJ J Kavanagh, P B Saul, L J Copeland, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 27, 1999
Novel GLRA1 missense mutation (P250T) in dominant hyperekplexia defines an intracellular determinant of glycine receptor channel gatingB Saul, T Kuner, D Sobetzko, et al.
Pageof 7